Insight

Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Photo taken from Piotr Wysocki/LinkedIn

Mar 23, 2024, 04:35

Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?

Piotr Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital, recently shared on LinkedIn:

“I want to share with you my personal view on the optimal utilisation of currently available treatments for advanced HR+/HER2- breast cancer. The review published online in JCO Oncology Practice summarizes the available data on the efficacy and safety of various therapeutic strategies in relationship to current reimbursement limitations in Poland and many other EU countries (lack of reimbursement of everolimus and unavailability of capivasertib). You can download the whole paper here.”

Source: Piotr Wysocki/LinkedIn

Breast Cancer cancer Capivasertib endocrine treatment everolimus HR+/HER2- breast cancer JCO Oncology Practice OncoDaily Oncology Piotr Wysocki Poland review treatments for cancer

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage